Why animal models still matter in drug development Patient advocates warn that political momentum to reduce animal testing is outpacing the scientific validation of alternative methods. Written byBree Foster, PhD

https://www.drugdiscoverynews.com/why-animal-models-still-matter-in-drug-development-17275 Governments around the world are moving to reduce the use of animal models in preclinical research, driven by ethical concerns and rapid advances in new approach methodologies (NAMs). In the US, this transition has been accelerated by recent legislative changes. The FDA Modernization Act 2.0, enacted in 2022, removed the decades-old statutory requirement that animal testing be included in Investigational New Drug applications. Three years later, FDA Modernization Act 3.0 went further, directing the FDA to establish a formal process for qualifying nonclinical testing methods.